帕利哌酮缓释片治疗精神分裂症的对照研究

目的探讨帕利哌酮缓释片治疗精神分裂症的疗效和安全性。方法86例精神分裂症患者按治疗疗法不同分为治疗组和对照组，分别给予帕利哌酮缓释片和利培酮治疗8周，采用阳性症状和阴性症状量表（PANSS）评定临床疗效，副反应量表（TESS）评定药物不良反应。结果治疗8周后两组疗效相当，治疗组和对照组的有效率分别为79．07％和76．74％，两组比较差异无统计学意义Z=-0．567，P=0．571）。治疗组不良反应的发生率显著低于对照组，两组比较差异有统计学意义（χ^2=17．12，P=0．00）。结论帕利哌酮缓释片治疗精神分裂症起效快，疗效确切，不良反应轻微，安全性好。

Control study of paliperidone extended-release tablets on treatment of schizophrenia

Objective To evaluate the efficacy and safety of paliperidone extended-release tablets on the treatment of schizophrenia. Methods In 8-week study, 86 schizophrenic patients were assigned into two groups , 43 patients in each group. The treatment group was given paliperidone extended-release tablets and the control group was given risperidone. The positive and negative symptom scale （PANSS） was used to evaluate the efficacy. The treatment emergent symptom scale （TESS） was used to assess the adverse reactions. Results The patients in both groups had significant efficacy after 8-week study. There were no significant differences in the efficacy between the two groups （Z=-0.567,P = 0.571）. The adverse reactions of paliperidone extended-release tablets was lower than that of risperidone, the differences were significant （χ^2=17.12,P = 0.00）. Conclusion Paliperidone extended-release tablets had the advantage of quick response in the treatment of. schizophrenia, and had the advantages of a considerable effect similar to risperidone and high safety.